Trichloromethanesulfenate antimicrobial agents for biofilm eradication
Novel phenyl trichloromethanesulfenate compounds that demonstrate potent antimicrobial activity against planktonic bacteria and mature biofilms, including Staphylococcus epidermidis and Pseudomonas aeruginosa. These scalable derivatives offer promising applications as disinfectant compositions and potential antibiotic candidates.
Overview
This technology centers on trichloromethanesulfenate ester compounds, specifically phenyl trichloromethanesulfenates, as novel antimicrobial agents. These compounds have demonstrated significantly enhanced potency against both planktonic bacteria and mature biofilms compared to their parent phenol structures. Testing against Staphylococcus epidermidis and Pseudomonas aeruginosa showed mean fold improvements in minimum inhibitory concentration of 44-fold and 16-fold respectively. The trichloromethylthio functional group responsible for antimicrobial activity is also found in Captan, a widely used agricultural antifungal, suggesting strong potential for industrial-scale production. Applications include standalone disinfectant compositions, combination formulations with quaternary ammonium salts, and potential new antibiotic classes through trichloromethanesulfenyl amide derivatives.
Technical specifications
Key features and capabilities:
- Demonstrated micromolar efficacy against gram-positive bacteria including Staphylococcus epidermidis
- Effective against mature biofilms of both gram-positive and gram-negative organisms
- Markedly improved potency compared to parent phenol compounds
- Compounds 7b, 8b, and 25b identified as lead candidates with validated antimicrobial profiles
- Potential for combination use with quaternary ammonium salts for enhanced disinfectant formulations
- Extension to trichloromethanesulfenyl amides proposed for antibiotic development
- Scalable synthesis pathway supported by structural similarity to commercially produced Captan
Technology readiness level
The technology is at an early-to-mid stage of development. Initial validation has been completed through published peer-reviewed research demonstrating efficacy against planktonic cells and biofilms of clinically relevant bacterial species. Future validation plans include expanded testing of phenyl trichloromethanesulfenates as disinfectant compositions, both alone and in combination with quaternary ammonium salts, as well as evaluation of trichloromethanesulfenyl amide derivatives as potential antibiotics using established protocols. Additional studies are needed to advance toward commercial application.
About Montana State University
Montana State University's substantial research enterprise growth has been accompanied by focused investments in innovation and research translation, creating new opportunities for companies to engage with MSU research and expertise. A particular strength is MSU’s network of specialized centers, institutes, and industry-accessible core facilities, which bring together multidisciplinary expertise, advanced research infrastructure, testing capabilities, and established pathways for working with industry partners. MSU is one of a select group of universities participating in the NSF's Accelerating Research Translation (ART) program, which is building the capacity and infrastructure needed to translate more research discoveries into solutions with real-world impact. The growing MSU Innovation Campus and expanding incubator infrastructure provide additional opportunities for university-industry interaction, startup development, and technology-focused companies. These efforts are complemented by MSU’s Technology Transfer Office, which works with researchers and companies to protect and license MSU inventions and facilitate industry-sponsored research collaborations.
delivered to your inbox.